Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | NAMPT | P43490 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13594297 | 0.81 | CHRM3 (0.53) | CHRM5CHRM3EPHX2NAMPTHTT | |
| SCHEMBL2523817 | 0.81 | OPRL1 (0.53) | ALDH1A1OPRL1OPRM1 | |
| SCHEMBL13182941 | 0.79 | CHRM5 (0.53) | CHRM5CHRM3EPHX2NAMPTHTT | |
| SCHEMBL2473530 | 0.79 | CHRM5 (0.53) | CHRM5CHRM3EPHX2NAMPTHTT | |
| SCHEMBL13182920 | 0.79 | CHRM5 (0.53) | CHRM5CHRM3EPHX2NAMPTHTT | |
| SCHEMBL2473435 | 0.79 | CHRM5 (0.53) | CHRM5CHRM3EPHX2NAMPTHTT | |
| SCHEMBL2701618 | 0.78 | KMT2A (0.56) | AR | |
| SCHEMBL14327363 | 0.78 | CHRM5 (0.49) | CHRM5CHRM3EPHX2NAMPTHTT | |
| SCHEMBL12194678 | 0.78 | CHRM5 (0.52) | CHRM5CHRM3EPHX2NAMPTHTT | |
| SCHEMBL12194770 | 0.77 | GFER (0.53) | CHRM5CHRM3EPHX2NAMPTOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | CHRM5 676/4885CHRM3 1015/4885EPHX2 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.